



## CASE SERIES

IRCCS Policlinico Universitario Fondazione A. Gemelli

Camillo Marra

email

[camillo.marra@policlinicogemelli.it](mailto:camillo.marra@policlinicogemelli.it)

28/11/2022

# 1 Case Series Description

**Age Range:** 50-85

**Size N:** 1500 subjects

**Recruitment:** 2018-2022 (ongoing)

**Data collection:** 2018-2022 (ongoing)

**Healthy controls:** no

**Only at-risk gene carriers included:** no

**Diseases studied:**

Alzheimer Disease (AD)  
Subjective Cognitive Complaints (SCC)  
Mild Cognitive Impairment (MCI)  
Vascular Dementia (VaD)  
Frontotemporal Dementia (FTD)  
Lewy Bodies Dementia (DLB)  
Parkinson Disease (PD)  
Multiple System Atrophy (MSA)  
Progressive Supranuclear Palsy (PSP)  
Corticobasal Degeneration (CBD)  
Creutzfeldt-Jakob Disease (CJD)

## **Clinical Evaluation:**

- Neuropsychological Assessments (all subjects): Mini-Mental State Examination, Rey Auditory Verbal Learning Test (RAVLT), Rey-Osterrieth Complex Figure (ROCF) copy and 15-minutes delayed recall, Stroop test, Multiple Feature Target Cancellation (MFTC), digit span forwards and backwards, Raven's Progressive Matrices, Object Naming on Picture Presentation, Phonological Verbal Fluency, Category Verbal Fluency, Trail Making Test
- Other (selected subjects): Neuropsychiatric Inventory, Frontal Assessment Battery, Visual Object and Space Perception Battery, Screening for Aphasia NeuroDegeneration, Esame Neuropsicologico dell'Afasia, Free and Cued Selective Reminding Test, Wisconsin Card Sorting Test, etc.

## **Imaging and Neurophysiology:**

- EEG (approximately 100 subjects)
- MRI 1.5 T (approximately 80 subjects)
- FDG-PET (approximately 150 subjects)

- Amyloid PET (approximately 80 subjects)
- DaT-SPECT (approximately 25 subjects)
- Myocardial MIBG scintigraphy (approximately 10 subjects)

**Genotyping:**

- APOE-4 (for a subsample)

**Digital Data obtained from patients through electronic devices:** 30 subjects

**Biological Samples:**

- CSF (approximately 350 subjects)
- Plasma (approximately 300 subjects)
- Serum (approximately 300 subjects)

**Follow-up:**

- Number of Follow-ups planned: 5 years
- Number of Follow-ups completed: na
- Average duration between follow-ups (years): 0.5-1 years
- Follow-ups type: Clinical evaluation, other exams only for a subsample of subjects